GW was founded in 1998. GW Pharmaceuticals has "high" hopes that its products will help relieve the pain and muscle stiffness that have resulted from cancer, multiple sclerosis, and surgery. The company develops prescription medicinal drugs derived from an hybrid form of cannabis that doesn't cause a psychotropic high. GW's lead drug candidate is Sativex, a whole-plant cannabis extract delivered by an oral spray. Sativex has been approved in Canada for the treatment of pain caused by multiple sclerosis. The company has agreed to let Bayer market the drug in the UK and Canada.

Quintiles Transnational has plenty to CRO about. One of the world's top contract research organizations (CROs), with operations in more than 50 countries, it helps drug and medical device companies develop and sell their products. The firm provides a comprehensive range of clinical trials management services, including patient recruitment, data analysis, laboratory testing, and regulatory filing. Its consulting unit offers strategic advice at every stage of drug discovery and development, and its Innovex subsidiary is a contract sales organization providing sales personnel to promote approved products. An investment group led by founder and CEO Dennis Gillings owns the company.

Vivalis SA was founded in 1999 and is headquartered in Saint-Herblain, France. Vivalis SA, a biopharmaceutical company, develops and sells cell-based solutions to the pharmaceutical industry for the manufacture of viral vaccines and therapeutic proteins. Its proprietary technologies include EB66 cell line platform, which is derived from duck embryonic stem cells that presents industrial and regulatory characteristics to replace the eggs in the production of vaccines and to produce antibodies with enhanced antibody dependent cell cytotoxicity activity; and the 3D-SCREEN molecular screening platform that is used to identify and develop molecules for the purpose of blocking the action of proteins involved in major viral pathologies. The company also develops drugs for the prevention and treatment of viral diseases, notably for the treatment of hepatitis C.

Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) provides research and development support for the pharmaceutical business units of parent company, Johnson & Johnson. Its main research processes are divided into three franchises: central nervous system and internal medicine; biotech, immunology, and oncology (through J&J subsidiary Centocor); and virology (through Tibotec). The subsidiary -- which represents the largest segment of J&J's pharmaceutical R&D -- also does research in collaboration with other pharmaceutical organizations and biotech researchers, and has partnerships with the likes of Basilea Pharmaceuticals and Entelos.

Inovio Biomedical Corporation was founded in 1983 and is based in San Diego, California. Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company's SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio's proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio's clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, NIH Vaccine Research Center, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

Evotec AG (Evotec) is a drug discovery and development company focused on small molecule therapeutics. Evotec is developing treatments for diseases in the areas of neuroscience, pain, and inflammation. Evotec’s portfolio comprises five clinical drug candidates: EVT 101, a subtype selective NMDA receptor antagonist with potential for the treatment of Alzheimer’s disease, pain and depression, EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 302, a MAO-B inhibitor in development for smoking cessation, a P2X7 antagonist for the treatment of inflammatory diseases, and a small molecule vanilloid receptor (VR1) antagonist for the treatment of pain in partnership with Pfizer. Evotec’s late stage preclinical research programs focus on EVT 103, a back-up compound to EVT 101, H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor P2X3 for the treatment of pain.

CK Life Sciences champions good health and sustainable growth in its business and elsewhere. The company specializes in the development of yeast-based fertilizers and nutritional supplements. Its VitaGain line of nutritional products are sold in Asia. In the US its Vitaquest International (doing business as Garden State Nutritionals) subsidiary is a contract manufacturer of nutritional supplements. Its Australian subsidiaries manufacture commercial and retail fertilizers and gardening products. Other subsidiaries conduct biotech research and development. CK Life Sciences is part of Cheung Kong.

Affymax, Inc. company was founded in 2001 and is based in Palo Alto, California. Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide.

Takeda San Diego develops high-throughput protein crystallography systems used to speed up the drug discovery process. The company's technology can detect the three-dimensional shape of proteins, an important step in determining how a drug can be attached to a protein to produce a therapeutic effect. The US biotech developer is one of Japanese drug maker Takeda's main research and development facilities. The subsidiary's drug discovery know-how is being used to develop new therapies for metabolic diseases such as diabetes, cancer, and inflammatory conditions.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.